Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial, investigating nadunolimab in first-line non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy. Cantargia reported positive efficacy data from the PDAC arm of CANFOUR in May 2021, while the latest available data from the NSCLC arm was presented at the ESMO Congress in September 2021. With these data, Cantargia is preparing to engage with regulators to discuss Phase III development plans for nadunolimab in PDAC. Its clinical footprint is already expanding beyond the CANFOUR trial, with the Phase I/III CAPAFOUR trial initiating in August (FOLFIRINOX combination for PDAC). Additional Phase I/II trials for CAN04 are in various stages in other solid tumours, including TNBC (TRIFOUR) and colorectal, biliary tract cancer and second-line NSCLC (CESTAFOUR).
Increasing the understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.